ILD-SARDs Registry and Biorepository — ILD-SARDs  

Systemic Lupus Erythematosus Clinical Trial

Official title: Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (ILD-SARDs) Registry and Biorepository

Status Recruiting

Clinical Trial Summary

A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs. The purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.

Clinical Trial Description

1. BACKGROUND AND STUDY RATIONALE: Characterized by immune dysregulation with disrupted self-tolerance, systemic autoimmune rheumatic diseases (SARDs) result in inflammation and auto-antibody formation that cause multi-tissue damage. The prototypic SARDs are rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and autoimmune myositis (AIM). The lung is a frequent target of autoimmune-mediated injury in patients with SARDs, and interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with SARDs. Among patients with SARDs, ILD varies widely in terms of its morphological pattern, time course, severity and the specific immune cells and cytokines that are most responsible for lung damage. Fundamental clinical questions remain unanswered for understanding diagnosis and management of ILD-SARDs: 1. ILD-SARDs prediction: Which patients with SARDs are likely to develop ILD? In retrospective cohorts of patients with RA, a patient's risk of developing ILD can be predicted by their age, sex and presence of auto-antibodies. How these clinical features interact with possible genetic and environmental risk factors needs to be better established to identify SARDs patients most at risk of developing ILD and to design and test interventions that reduce that risk or delay the onset of clinical manifestations in high-risk patients. 2. ILD-SARDs pathogenesis in humans and preclinical models: Why is there considerable heterogeneity in ILD progression and severity in patients with ILD-SARDs? The fundamental changes that occur in the immune system and lungs of patients with ILD-SARDs are still poorly understood. This is in part due to a lack of appropriate pre-clinical models of ILD-SARDs and lung biopsies from patients with ILD-SARDs. Identifying the biologic processes that promote development of ILD in SARDs patients will let the Investigators use drugs for other ILDs to specific patients with ILD-SARDs and promote the development of new targeted therapies. 3. ILD-SARDs treatment: Which are the best therapies for patients with ILD-SARDs? Few proven treatments for patients with ILD-SARDs exist. Many are proposed based only on case reports in specific SARDs. Positive results from studies of anti-fibrotic agents patients show it is possible to reverse the fibrotic process; yet it is unclear whether some patients with ILD-SARDs could also benefit from this approach as it may interact with the immunosuppressive agents the participants already receive. Addressing this issue is critical to changing the natural course of ILD-SARDs, particularly the symptoms and outcomes most important to patients. The conduct of many of the related future studies will require access to genetic material, fresh peripheral blood cells, serum and tissue from a phenotypically well characterized group of patients with ILD-SARDs. Access to patients is required for future clinical research projects and participation in potential clinical trials. Furthermore, the ILD-SARDs Registry and Biorepository is similar to registries and biorepositories that have been developed or are being developed in Germany, Australia, the United States and elsewhere in Canada. These similarities will facilitate national and international collaboration and allow establishment of a global collaborative network that is essential for further advancement of ILD-SARDs. The aforementioned future studies that will benefit from the contributions of this Bank include the identification of cell types, immune modulators and genetic pathways dysregulated in ILD-SARDs patients; pre-clinical in vivo and ex vivo models to assess disease pathobiology and targeted interventions, such as mouse models to assess mechanisms in the initiation and progression of ILD in SARDs, as well as a human ILD-SARDs lung-on-a-chip model to assess and predict treatment effect by evaluation mechanical evolution of the tissue; the ILD-SARDs Patient Preferences study, which consists of the facilitation of focus groups to characterize ILD-SARDs patients' experiences, needs and preferences; and the existing open-label, single arm pilot study of the safety and tolerability of nintedanib in patients with ILD and autoimmune inflammatory myopathy, to assess the effect of nintedanib on the state of activation of AIM patients' blood cells and to define its effect on the immunophenotype of circulating blood cells in patients. 2. OBJECTIVES, HYPOTHESIS AND STUDY QUESTIONS A complex interplay between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Co-morbidity and extensive sharing of genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs. The multidisciplinary team will examine this hypothesis through the establishment of a prospective registry of patients with ILD-SARDs to be enrolled and followed longitudinally, combined with a biorepository. 3. STUDY METHODS The Investigators will develop a longitudinal clinical registry and biorepository of ILD-SARDs patients. Patient recruitment, informed consent, management, storage of data/samples and all other research activities will be done in accordance with the ILD-SARDs Biobank Management Framework. The ILD-SARDs informed consent forms will be used to obtain participant consent. To estimate recruitment in this cohort, the Investigators reviewed the number of patients seen in the multispecialty ILD-SARDs clinic at the McGill University Health Centre (MUHC) over the last year. The Investigators will recruit an inception cohort for biobanking with annual collection of structured clinical data. Clinical data - including clinical rheumatologic and pulmonary assessment, serology, pulmonary function tests, CT imaging, pathology, current treatments - will be collected at every visit. A biorepository will store biological specimens such as blood cells, serum and DNA/RNA for the cohort members. More specifically, the Investigators will collect whole blood samples at visits as defined above. Those belonging to treatment-naive patients will be sent to Dr. David Langlais' lab at the Inflammation Genomics Lab of the McGill University Genome Centre for single cell RNA sequencing and immunophenotyping. A Standard Operating Process (SOP) for blood sampling, shipping and storage has been developed to detail this process. As for whole blood samples coming from non-treatment-naive-patients, those will be sent to Dr. Gregory Fonseca's lab at the Meakins-Christie Lab at the Royal Victoria Hospital to be processed, and the resulting serum will be biobanked. Moreover, patients with an available bronchoalveolar lavage, lung, skin or muscle biopsy, as well as blood samples will be asked for consent for the study staff to access those samples for the purpose of this research. These samples are essential for the mechanisms established in future studies and will help enable them. The PIs, working under different disciplines, will all equally contribute to the study by identifying eligible participants, having medical oversight and study conduct, having written confirmation of inclusion/exclusion criteria, conducting a physical exam, assessing and signing adverse events (AEs) and serious adverse events (SAEs), providing medical care and follow-up to the participant and reviewing, interpreting and signing lab and other test results. Together, this will allow for a larger number of participants to be identified and followed up in this study. ;

Related Conditions & MeSH terms

• Arthritis
• Autoimmune Diseases
• Collagen Diseases
• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial
• Lupus Erythematosus, Systemic
• Myositis
• Nonspecific Interstitial Pneumonia
• Pneumonia
• Rheumatic Arthritis
• Rheumatic Diseases
• Rheumatic Fever
• Scleroderma, Diffuse
• Scleroderma, Systemic
• Sclerosis
• Systemic Autoimmune Disease
• Systemic Lupus Erythematosus
• Systemic Sclerosis
• Usual Interstitial Pneumonia

• NCT number: NCT05007340
• Study type: Observational [Patient Registry]
• Source: McGill University Health Centre/Research Institute of the McGill University Health Centre
• Contact: Deborah Assayag, MD, MAS
• Phone: 514-934-1934
• Email: deborah.assayag@mcgill.ca
• Status: Recruiting
• Start date: August 24, 2021
• Completion date: August 2026